Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Dan Smith

Gastroenterology Oklahoma City, OK Medical Doctor

NPI 1104801562 CMS profile 185837

3366 Nw Expressway, Oklahoma City, OK 73112

Open in the dashboard

General payments

$569

41 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Dan Smith of Oklahoma City, OK is reported in the CMS Open Payments database as having received $569 across 41 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 27th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $20 1
2023 General $47 3
2022 General $191 12
2021 General $109 7
2020 General $86 6
2019 General $116 12

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Dan Smith
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Dan Smith were reported at $0. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Dan Smith Gastroenterology median Middle half National median
2019 $116 $417 $126–$1,100 $163
2020 $86 $224 $74–$624 $114
2021 $109 $352 $106–$1,054 $132
2022 $191 $448 $129–$1,270 $149
2023 $47 $533 $150–$1,390 $160
2024 $20 $605 $160–$1,606 $164
2025 $0 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Janssen Biotech, Inc. $173 15 payments
  2. AbbVie, Inc. $111 5 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $77 5 payments
  4. QOL Medical, LLC $53 4 payments
  5. Salix Pharmaceuticals, a division of Bausch Health US, LLC $38 3 payments
  6. Regeneron Healthcare Solutions, Inc. $32 2 payments
  7. Abiomed $20 1 payment
  8. Ardelyx, Inc. $16 1 payment
  9. Ironwood Pharmaceuticals, Inc $16 1 payment
  10. Boehringer Ingelheim Pharmaceuticals, Inc. $14 1 payment
  11. Other $19 3 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $569 41 payments
Products named General payments · program years 2019–2024
  1. STELARA $173 15 payments
  2. HUMIRA $89 4 payments
  3. Sucraid $53 4 payments
  4. XIFAXAN $51 4 payments
  5. GATTEX $42 3 payments
  6. ENTYVIO $36 2 payments
  7. DUPIXENT $32 2 payments
  8. RINVOQ $21 1 payment
  9. Impella $20 1 payment
  10. SIMPONI $16 1 payment
  11. Other $75 10 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 14 billing codes

Paid by Medicare

$11,155

Medicare's payments for the services billed

Medicare patients

59

Average age 76

Services billed

134

33 women, 26 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 61%
Diabetes 51%
Ischemic heart disease 51%
Chronic kidney disease 51%
Atrial fibrillation 47%
Heart failure 46%
COPD 37%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

41 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Oklahoma

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record